Last reviewed · How we verify
Nebulised Bupivacaine intraperitoneally
Nebulised bupivacaine delivered intraperitoneally provides local anesthetic effect to reduce postoperative pain and inflammation within the peritoneal cavity.
Nebulised bupivacaine delivered intraperitoneally provides local anesthetic effect to reduce postoperative pain and inflammation within the peritoneal cavity. Used for Postoperative pain reduction following abdominal surgery.
At a glance
| Generic name | Nebulised Bupivacaine intraperitoneally |
|---|---|
| Also known as | Marcaine |
| Sponsor | Imperial College London |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain management / Surgery |
| Phase | Phase 3 |
Mechanism of action
Bupivacaine is a long-acting local anesthetic that blocks sodium channels in nerve fibers, inhibiting pain signal transmission. When nebulised and delivered intraperitoneally during or after abdominal surgery, it achieves high local concentrations at visceral and parietal peritoneal surfaces, reducing acute postoperative pain without systemic absorption. This approach aims to minimize opioid requirements and improve recovery outcomes.
Approved indications
- Postoperative pain reduction following abdominal surgery
Common side effects
- Local tissue irritation
- Systemic bupivacaine toxicity (if absorbed)
- Peritoneal inflammation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: